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Abstract
Growing evidence indicates that the deregulation of microRNAs (miRNAs) contributes to the tumorigenesis. We previously
revealed that microRNA-520b (miR-520b) was involved in the complement attack and migration of breast cancer cells. In
this report, we show that miR-520b is an important miRNA in the development of hepatocellular carcinoma (HCC). Our data
showed that the expression levels of miR-520b were significantly reduced in clinical HCC tissues and hepatoma cell lines. We
observed that the introduction of miR-520b dramatically suppressed the growth of hepatoma cells by colony formation
assays, 5-ethynyl-2-deoxyuridine (EdU) incorporation assays and 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assays. Moreover, ectopic expression of miR-520b was able to inhibit the growth of hepatoma cells in
nude mice. Further studies revealed that the mitogen-activated protein kinase kinase kinase 2 (MEKK2) and cyclin D1 were
two of direct target genes of miR-520b. Silencing of MEKK2 or cyclin D1 was able to inhibit the growth of hepatoma cells in
vitro and in vivo, which is consistent with the effect of miR-520b overexpression on the growth of hepatoma cells. In
addition, miR-520b significantly decreased the phosphorylation levels of c-Jun N-terminal kinase (p-JNK, a downstream
effector of MEKK2) or retinoblastoma (p-Rb, a downstream effector of cyclin D1). In conclusion, miR-520b is able to inhibit
the growth of hepatoma cells by targeting MEKK2 or cyclin D1 in vitro and in vivo. Our findings provide new insights into
the role of miR-520b in the development of HCC, and implicate the potential application of miR-520b in cancer therapy.
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Introduction
MicroRNAs (miRNAs) belong to a class of small, highly
conserved noncoding RNAs known to suppress the expression of
protein-coding genes through imperfect complementarity with the
39-untranslated region (39UTR) of target messenger RNA
(mRNA) [1]. Accumulating evidence has shown that miRNAs
can function as oncogenes or tumor suppressors involved in cancer
development, including tumor metastasis and proliferation [2,3,4].
Many studies demonstrate that miRNAs have essential roles in
hepatocellular carcinoma (HCC) progression and directly contrib-
ute to cell proliferation and metastasis of HCC by targeting a large
number of critical protein-coding genes. For example, overex-
pression of miR-26a induces HCC cell cycle arrest. Cyclin D2 and
cyclin E2 are validated as direct targets of miR-26a, which exhibits
reduced expression in HCC [5]. MiR-21, miR-221 and miR-222
contribute to the proliferation and metastasis of HCC cells by
targeting phosphatase and tensin homolog (PTEN) [6,7]. MiR-122
is significantly downregulated in liver cancer and suppresses HCC
intrahepatic metastasis by regulation of a disintegrin and
metalloprotease family proteins ADAM10 and ADAM17 [8,9].
Although a large number of miRNAs have been identified, their
roles in HCC development and the underlying mechanisms still
need to be explored. We have reported that miR-520b is
downregulated in breast cancer cells relative to normal breast
cells, and sensitizes breast cancer cells to complement attack via
directly targeting 39UTR of CD46 [10]. Recently, research in our
laboratory has revealed that miR-520b inhibits the migration of
breast cancer cells by targeting interleukin-8 (IL-8) and hepatitis B
X-interacting protein (HBXIP) [11]. However, the roles of miR-
520b in the growth of hepatoma cells remain unclear.
Cyclin D1 is a cell cycle regulator. Aberrant expression of cyclin
D1 can lead to abnormal cellular proliferation [12]. Mitogen-
activated protein kinase kinase kinase 2 (MEKK2), a member of
the MAPK signaling pathway, is able to activate c-Jun N-terminal
kinase (JNK) and ERK5 [13,14]. MEKK2 knockout mouse studies
have revealed that MEKK2 has important functions in the T-cell
receptor, epidermal growth factor (EGF) and fibroblast growth
factor 2 (FGF-2) signaling pathways [13,15,16]. It has been
reported that MEKK2 is able to discriminate tumor from normal
cells [17], suggesting that MEKK2 may play important roles in the
development of cancer.
In the present study, we showed that miR-520b was
downregulated in HCC tissues and hepatoma cell lines. Our
finding shows that miR-520b is able to inhibit the growth of
hepatoma cells by targeting MEKK2 and cyclin D1 in vitro and in
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31450vivo. Our data provide new insights into the role of miR-520b in
the development of HCC.
Results
MiR-520b is downregulated in HCC tissues and
hepatoma cell lines
Previous study in our laboratory showed that the expression
level of miR-520b was downregulated in breast cancer cells
compared with normal breast cells [10]. To further investigate the
roles of miR-520b in the development of HCC, we analyzed the
expression level of miR-520b in 11 paired clinical HCC tissues and
adjacent noncancerous liver tissues by quantitative reverse-
transcription PCR (qRT-PCR). Clinical characteristics of the
patients are listed in Table S1. Compared with their peritumor
tissues, significant downregulation of miR-520b was observed in
clinical HCC tumor tissues (Fig. 1A, **P,0.01, Student’s t test).
Meanwhile, the expression levels of miR-520b were reduced in 4
hepatoma cell lines relative to 2 normal liver cell lines (Fig. 1B,
*P,0.05, Student’s t test). The data suggest that the expression
level of miR-520b is downregulated in human HCC.
MiR-520b inhibits growth of heptoma cells in vitro
We demonstrated that the expression level of miR-520b in
pcDNA3-520b transfected HepG2 cells was higher than that in
pcDNA3 transfected cells by qRT-PCR (Fig. 2A, **P,0.01,
Student’s t test). A more than ten-fold increase in the expression of
miR-520b was observed in HepG2 cells transfected with 100 nM
miR-520b mimics (termed miR-520b) relative to the cells transfected
with 100 nM miR-520b negative control (termed miR-NC) (Fig. 2A,
**P,0.01, Student’s t test). Colony formation analyses indicated that
the growth ability of pcDNA3-520b transfected cells was lower than
thatofpcDNA3 transfected cells(Fig.2B, **P,0.01,Student’sttest).
The 5-ethynyl-2-deoxyuridine (EdU) incorporation assays showed
that the growth of HepG2 cells and H7402 cells was significantly
inhibited by 100 nM miR-520b relative to 100 nM miR-NC
(Fig.2C,**P,0.01,Student’sttest).Meanwhile,miR-520binhibitor
(termed Inh-520b) enhanced the growth of HepG2 cells and H7402
cells compared with the inhibitor negative control (termed Inh-NC)
(Fig. 2D, **P,0.01, Student’s t test). Next, 3-(4,5-dimethylthiazol-2-
yl)-2,5- diphenyltetrazolium bromide (MTT) assays demonstrated
that the transient overexpression of miR-520b resulted in the
inhibition of the growth of HepG2 and H7402 cells; while Inh-520b
significantly attenuated the suppression (Fig. 2E, *P,0.05,
**P,0.01, Student’s t test). Thus, our data indicate that miR-520b
is able to inhibit the growth of hepatoma cells in vitro.
MiR-520b suppresses tumorigenicity of hepatoma cells in
vivo
We further investigated the function of miR-520b in vivo using
xenograft model. Stably pcDNA3-520b-tranfected HepG2 cells
were injected subcutaneously into 6 female BALB/c athymic nude
mice, respectively. After 4 weeks, we found that introduction of
pcDNA3-520b into HepG2 cells led to a significant reduction of
tumor volume. qRT-PCR analyses demonstrated that the
expression levels of miR-520b were obviously increased in
pcDNA3-520b tumors compared with control tumors (Fig. 3A,
B and C, *P,0.05, Student’s t test). The data provide evidence
that miR-520b can inhibit the growth of hepatoma cells in vivo.
MiR-520b directly inhibits expression of MEKK2 and
cyclin D1 via their 39UTR
To explore the mechanisms of miR-520b-induced cell growth
inhibition, we searched for the target genes of miR-520b. The
regions complementary to miR-520b seed region in the 39UTR of
human MEKK2 or cyclin D1 mRNA were observed by using
DIANA microT v3.0 algorithm (Fig. 4A), which was also
confirmed by TargetScan and PicTar. To validate whether
MEKK2 and cyclin D1 were the direct target genes of miR-
520b, a dual-luciferase reporter system was employed. We cloned
39UTR sequences containing the predicted target site (wild type,
WT) of miR-520b or mutated sequences (mutant type, Mut) into
the pGL3 control vector, respectively. The data showed that the
co-expression of miR-520b mimics significantly suppressed the
firefly luciferase activities of the reporter with wild type 39UTR but
not that of the mutant reporter (Fig. 4B, *P,0.05, **P,0.01,
Student’s t test), indicating that miR-520b can directly target the
39UTR of MEKK2 and cyclin D1. The effect of miR-520b on
endogenous expression of MEKK2 and cyclin D1 was subse-
quently examined by western blot. Transfection of miR-520b
resulted in an obvious downregulation of MEKK2 and cyclin D1
at the protein levels in HepG2 and H7402 cells. Meanwhile, miR-
520b inhibitor was able to upregulate the expression of MEKK2
and cyclin D1 in the cells (Fig. 4C). Western blot analyses showed
that the expression levels of MEKK2 and cyclin D1 were
Figure 1. MiR-520b is downregulated in HCC tissues and hepatoma cell lines. (A) The relative expression of miR-520b in clinical HCC
patients was examined by qRT-PCR. (B) The relative expression of miR-520b in hepatoma cells and normal liver cells was examined by qRT-PCR.
*P,0.05, **P,0.01, Student’s t test.
doi:10.1371/journal.pone.0031450.g001
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(Fig. 3) relative to control tumors (Fig. S1). It suggests that miR-
520b is able to downregulate the expression of MEKK2 and cyclin
D1 in the tumor cells.
MiR-520b targeted MEKK2 and cyclin D1 contribute to
growth of hepatoma cell in vitro and in vivo
To explore whether miR-520b targeted MEKK2 or cyclin D1 is
responsible for the inhibition of the growth of hepatoma cells, we
examined the effects of knockdown of target genes on the growth
of hepatoma cells. Western blot analyses demonstrated that both
of two siRNAs targeting MEKK2 (or cyclin D1) were able to
effectively knockdown the expression of MEKK2 (or cyclin D1) in
HepG2 cells and H7402 cells (Fig. 5A). Colony formation assays
showed that knockdown of MEKK2 (or cyclin D1) was able to
significantly decrease the colony formation capability in HepG2
(or H7402) cells transfected with two siRNAs targeting MEKK2
(or cyclin D1) relative to control (termed NC) (Fig. 5B, **P,0.01,
Student’s t test). Then, we chose one of siRNAs (termed
siMEKK2-1 or sicyclinD1-1) targeting MEKK2 or cyclin D1 to
perform EdU and MTT assays, respectively. EdU assays showed
that the silencing of the genes led to a significant reduction of
growth of HepG2 cells and H7402 cells (Fig. 5C, **P,0.01,
Student’s t test). The silencing efficiency MEKK2 and cyclin D1
were showed by western blot analyses in the experiment (Fig. 5C).
MTT assays showed that the transfection of miR-520b or silencing
the two target genes (or one gene) was able to dramatically
decrease the growth of hepatoma cells relative to controls, miR-
Figure 2. MiR-520b inhibits growth of hepatoma cells in vitro. (A) The expression levels of miR-520b were tested by qRT-PCR in HepG2 cells
transfected with pcDNA3, pcDNA3-520b, 100 nM miR-520b negative control (termed miR-NC) and 100 nM miR-520b mimics (termed miR-520b). (B)
The effect of pcDNA3-520b or pcDNA3 on the growth of HepG2 and MHCC-97L cells was examined by colony formation assay. Data are
representative of three independent experiments. (C) The effect of transient transfection of miR-520b or miR-NC on the growth of HepG2 and H7402
cells was examined by EdU incorporation assay. (D) The effect of transient transfection of miR-520b inhibitor (termed Inh-520b) or miR-520b inhibitor
negative control (termed Inh-NC) on the growth of HepG2 and H7402 cells was examined by EdU incorporation assay. (E) HepG2 and H7402 cells
were transfected with 100 nM miR-NC, 100 nM miR-520b, 200 nM Inh-NC and 200 nM Inh-520b, respectively. The effects of miRNAs on cell
proliferation were determined by MTT assay at 0h, 24h and 48h after transfection. *P,0.05, ** P,0.01, Student’s t test.
doi:10.1371/journal.pone.0031450.g002
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Student’s t test). To further determine the effect of miR-520b
targeted MEKK2 or cyclin D1 on growth of hepatoma cells in vivo,
the HepG2 cells transiently transfected with siRNAs targeting
MEKK2 or cyclin D1 were subcutaneously injected into 4- to 6-
week-old BALB/c athymic nude mice. Four days after injection,
we found that three group mice (NC, siMEKK2 and sicyclinD1)
all formed tumors and the average tumor volumes from the groups




3, respectively. Seven days later, NC group continually
grew. But the tumors of siMEKK2 and sicyclinD1 groups stop to
grow, we did not find any tumors 4 weeks latter (Fig. 5E),
suggesting that MEKK2 and cyclin D1 play very important roles
in hepatocarcinogenesis. Taken together, our finding suggests that
miR-520b targeted MEKK2 and cyclin D1 are involved in the
tumorigenicity of hepatoma cells in vitro and in vivo.
Cyclin D1 overexpression rescues miR-520b depressed
growth of hepatoma cells
It has been reported that JNK is one of downstream effectors of
MEKK2 [13]. Retinoblastoma (Rb) phosphorylation and cellular
growth are promoted by the activation of cyclin D1 in numerous
cancers [18]. We further examined the effect of miR-520b on
regulation of MEKK2 and cyclin D1 through determining the
phosphorylation levels of JNK (a downstream effector of MEKK2)
and Rb (a downstream effector of cyclin D1). We found that the
transfection with miR-520b in hepatoma cells led to the
downregulation of cyclin D1 and decreased the levels of p-Rb
(Fig. 6A). Meanwhile, we tested the expression of MEKK2 and p-
JNK in the cells as well (Fig. S2). The silencing of cyclin D1 (or
Figure 3. MiR-520b inhibits growth of hepatoma cells in vivo.
(A) The curve of tumor growth is shown. (B) Photograph of excised
tumors 4 weeks after implantation. (C) qRT-PCR analysis of miR-520b
expression in excised tumors was performed and normalized against an
endogenous control (U6 RNA).
doi:10.1371/journal.pone.0031450.g003
Figure 4. MiR-520b directly inhibits expression of MEKK2 and
cyclin D1 via their 39UTR. (A) Sequence alignment between miR-
520b and the 39UTR of human MEKK2 and cyclin D1 mRNA. Solid line,
seed match region; dashed line, seed-mutated region. (B) The effect of
miR-520b on the activity of firefly luciferase reporter containing either
wild type (WT) or mutant type (Mut) 39UTR was tested by luciferase
reporter gene assays. (C) The effect of miR-520b or Inh-520b on the
endogenous expression levels of MEKK2 and cyclin D1 was examined in
HepG2 and H7402 cells by western blot analyses. b-actin was used as an
internal control. The intensity for each band was quantified densitome-
trically.
doi:10.1371/journal.pone.0031450.g004
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31450Figure 5. MiR-520b targeted MEKK2 and cyclin D1 contribute to hepatoma cell growth in vitro and in vivo. (A) The expression levels of
MEKK2 and cyclin D1 were examined by western blot analyses in HepG2 and H7402 cells treated with two different siRNAs targeting MEKK2 (termed
siMEKK2-1 and siMEKK2-2) or two different siRNAs targeting cyclin D1 (termed sicyclinD1-1 and sicyclinD1-2). (B) The effect of transient transfection of
siRNAs targeting MEKK2 (siMEKK2-1 or siMEKK2-2) or cyclin D1 (sicyclin D1-1 or sicyclin D1-2) on the growth of HepG2 and H7402 cells was examined
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D1 and decrease the phosphorylation levels of Rb (or JNK) in the
cells as above. Interestingly, the overexpression of cyclin D1 was
able to rescue the miR-520b-decreased levels of p-Rb by transient
transfection with pcDNA3-cyclinD1 plasmids in HepG2 and
H7402 cells (Fig. 6B). These data support that MEKK2 and cyclin
D1 are two of targeting genes of miR-520b. Next, flow cytometry
analyses showed that the transient transfection with miR-520b led
to a decreased cell proliferation index (PI) from 72.25% to 42.69%
in HepG2 cells (**P,0.01, Student’s t test). However, the
introduction of cyclin D1 resulted in an increased cell PI (from
42.69% to 75.17%, **P,0.01, Student’s t test) and decreased the
percentage of cells in the G1 phase (from 53.26% to 24.83%) after
co-transfection with miR-520b and pcDNA3-cyclin D1 plasmids
(Fig. 6C). MTT assays showed that the enforced expression of
miR-520b dramatically inhibited the proliferation of hepatoma
cells and the overexpression of cyclin D1 was able to rescue miR-
520b-inhibited proliferation of HepG2 and H7402 cells (Fig. 6D).
Thus, our data suggest that cyclin D1 overexpression rescues the
inhibition of hepatoma cell growth mediated by miR-520b.
Discussion
Ectopic expression of miRNAs has been observed in various
types of cancers [19,20], but the current knowledge about
miRNAs function in HCC is still preliminary. Therefore,
identifying the miRNAs and their targets that are essential for
HCC progression may provide promising therapeutic opportuni-
ties. Our laboratory previously found that the expression level of
miR-520b was significantly downregulated in breast cancer cells.
miR-520b inhibits the migration of breast cancer cells [11].
However, the mechanism of miR-520b in the development of
cancer remains unclear. In this study, we focused on the
investigation of roles of miR-520b in growth of hepatoma cells
through its target genes.
We showed that miR-520b was downregulated in both HCC
tissues and hepatoma cell lines, suggesting that miR-520b might be
implicated in tumorigenesis (Fig. 1). Thus, we are interested in the
effect of miR-520b on tumor cell growth. Interestingly, the ectopic
expression of miR-520b inhibited the growth of hepatoma cells in
vitro and in vivo (Fig. 2 and 3), suggesting that the downregulation of
miR-520b may be responsible for the enhanced growth of
hepatoma cells and subsequently facilitate the development of
HCC. To explore the mechanism underlying the suppression of
hepatoma cell growth mediated by miR-520b, we next set out to
identify the target genes of miR-520b. According to bioinformatics
analysis, miR-520b may target many genes. Then, we chose two of
target genes of miR-520b, such as MEKK2 and cyclin D1 which
play important roles in the cell cycle and the cell growth, to
demonstrate the mechanism of miR-520b in regulation of the
growth of hepatoma cells. Our data show that miR-520b was able
to directly target the 39UTR of MEKK2 and cyclin D1. Western
blot analyses showed that the overexpression of miR-520b was
able to downregulate the expression of MEKK2 and cyclin D1 at
protein levels in HepG2 and H7402 cells (Fig. 4). Cyclin D1 is one
of the most important proteins regulating the cell cycle, and
related with the development of many cancers. The role of cyclin
D1 in cell proliferation is well demonstrated [12,21]. It leads to G1
cell cycle arrest and inhibits cell growth. MAPKs are very
important signaling components that convert extracellular stimuli
into cell proliferation. MEKK2 is a member of the MAPK
signaling pathway. Our data showed that silencing either MEKK2
or cyclin D1 was able to inhibit the growth of hepatoma cells in
vitro. Furthermore, tumor formation assays demonstrated that the
introduction of siMEKK2 or sicyclin D1 completely inhibited the
tumor growth in vivo (Fig. 5). These data suggest that MEKK2 or
cyclin D1 plays crucial roles in hepatocarcinogenesis. MEKK2
and cyclin D1 may serve as therapeutic targets of liver cancer.
MEKK2 is able to activate JNK. Subsequently, JNK regulates
multiple cellular functions including carcinogenesis [22]. Cyclin
D1 is involved in directly regulating Rb phosphorylation and cell
cycle progression. Hyperphosphorylation of Rb promotes cell
cycle progression and cell growth [23,24]. Here, our data showed
that miR-520b was able to downregulate the expression of cyclin
D1 or MEKK2 and decrease the levels of p-Rb (a downstream
effector of cyclin D1) or p-JNK (a downstream effector of
MEKK2), supporting that cyclin D1 and MEKK2 are two of
target genes of miR-520b. Furthermore, overexpression of cyclin
D1 was able to rescue the miR-520b-decreased levels of p-Rb and
proliferation of HepG2 and H7402 cells (Fig. 6 and S2). Thus, we
conclude that miR-520b inhibits the growth of hepatoma cells
through targeting MEKK2 and cyclin D1. Our findings provide
new insights into the role of miR-520b in the development of
HCC.
In summary, in this study we report that miR-520b is
downregualted in clinical hepatoma tissues and hepatoma cell
lines. MEKK2 and cyclin D1 are two of direct targets of miR-
520b. MiR-520b is able to inhibit the growth of hepatoma cells
through the target genes. Our findings implicate the potential
application of miR-520b as a tumor suppressor in cancer therapy.
Materials and Methods
Ethics statement
All HCC samples were obtained from patients who signed
informed consent approving the use of their tissues for research
purposes after operation. The study was approved by the
Institutional Review Board at the Nankai University and the
Institutional Review Board at Tianjin First Center Hospital. All
mouse experiments were approved by the Institutional Animal
Care and Use Committee at College of Life Sciences at Nankai
University (Approval ID 201009080081). Experimental proce-
dures were performed in accordance with the Guide for the Care
and Use of Laboratory Animals (NIH Publication No. 80-23,
revised 1996).
Patient samples
The 11 clinical HCC tissues and the corresponding nearby
noncancerous livers used in this study were obtained from patients
who underwent radical resection at Tianjin First Center Hospital
(Tianjin, China). Specimens were immediately frozen and stored
at 280uC. The relevant characteristics of the studied subjects were
shown in Table S1. Informed consent was obtained from each
patient and the study was approved by the Institute Research
Ethics Committee at Nankai University.
by colony formation assays. (C) The effect of transient transfection of sicyclin D1-1 or siMEKK2-1 on the growth of HepG2 and H7402 cells was
examined by EdU incorporation assays. (D) HepG2 and H7402 cells were transfected with miR-NC, miR-520b, NC, sicyclin D1-1 and/or siMEKK2-1,
respectively. The effects of miRNAs or siRNA targeting cyclin D1 or MEKK2 on hepatoma cell proliferation were determined by MTT assays at 24 h,
48 h and 72 h after transfection. *P,0.05, **P,0.01, Student’s t test. (E) Tumor growth measured after subcutaneous injection of HepG2 cells
transient transfected with NC, siMEKK2-1 or sicyclinD1-1. The tumor volume was calculated every 3 days. Points, mean (n=6); bars, SD.
doi:10.1371/journal.pone.0031450.g005
MicroRNA-520b Inhibits Growth of Hepatoma Cells
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31450RNA extraction and quantitative reverse transcription
PCR (qRT-PCR)
All RNA was extracted from cells or tissues with Trizol reagent
according to the manufacturer’s instructions (Invitrogen, Carlsbad,
CA). To quantify mature miR-520b expression, total RNA was
polyadenylated by poly (A) polymerase (Ambion, Austin, TX)
according to the manufacturer’s protocol. After reverse transcrip-
tion, qRT-PCR was performed using the quantitative SYBR
Green PCR kit (TaKaRa Bio, China). One primer is miRNA-
specific, and the other is a universal primer. U6 small nuclear
RNA was used as an internal normalized reference. To examine
the specificity of the qRT-PCR, the dissociation curve analysis was
Figure 6. Cyclin D1 overexpression rescues miR-520b depressed growth of hepatoma cells. (A) The effect of miR-520b or sicyclinD1-1 on
phosphorylation levels Rb (p-Rb) was examined in HepG2 and H7402 cells by western blot analyses. (B) Western blot analyses showed the expression
levels of cyclin D1 and p-Rb in HepG2 and H7402 cells treated by miR-520b or both pcDNA3-cyclin D1 and miR-520b. (C) The effect of cyclin D1
overexpression on the miR-520b-inhibited proliferation of HepG2 cells was examined by flow cytometry analyses. (D) The effect of cyclin D1
overexpression on the miR-520b-inhibited proliferation of HepG2 cells was examined by MTT assays at 24 h, 48 h and 72 h after transfection.
*P,0.05, ** P,0.01, Student’s t test.
doi:10.1371/journal.pone.0031450.g006
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Table S2.
Construction of plasmids
To construct a plasmid expressing miR-520b, we amplified the
fragment containing miR-520b precursor from HepG2 genomic
DNA. The amplified fragment was cloned into a pcDNA3 vector,
which was termed pcDNA3-520b. The amplified full-length cyclin
D1 from HepG2 cDNA was cloned into a pcDNA3 vector, termed
pcDNA3-cyclin D1. An empty pcDNA3 vector was used as
control. To construct 39UTR reporter plasmids, the 39UTR
fragments of human MEKK2 and cyclin D1 mRNA containing
the putative miR-520b binding site were amplified from HepG2
cDNA, and cloned into the region downstream of the firefly
luciferase gene in the pGL3 control vector (Promega, USA). To
introduce four-point-mutation into the seed region of the miR-
520b binding site, we used a PCR approach where the seeds
sequences were mutated in the primers. All primers used are listed
in Table S2.
Cell culture
Human HCC H7402 cell line, human immortalized liver L-O2
and Chang-liver cell lines were cultured in RPMI Medium 1640
(GIBCO, Grand Island, NY) containing 100 U/ml penicillin,
100 mg/ml streptomycin and 10% fetal calf serum (FCS, Life
Technologies, Carlsbad, CA). Human hepatoma HepG2 cell line,
human HCC MHCC-97H and MHCC-97L cell lines were
cultured in Dulbecco’s Modified Eagle’s medium (DMEM,
GIBCO-BRL, Grand Island, NY) containing 100 U/ml penicillin,
100 mg/ml streptomycin and 10% FCS supplemented with 10%
fetal bovine serum. To generate stably pcDNA3-520b- or
pcDNA3-transfected HepG2 cell lines, the transfection was
performed using Lipofectamine 2000 (Invitrogen). Forty-eight
hours after transfection, the transfected cells were incubated in
selection medium containing 800 mg/ml G418 (Genview, IL,
USA), continuously for 3–4 weeks. The successful stable
transfection of pcDNA3-520b into HepG2 cells was confirmed
by qRT-PCR.
MiRNA and RNA interference
MiR-520b mimics (miR-520b), miR-520b negative control
(miR-NC), miR-520b inhibitor (Inh-520b), miR-520b inhibitor
negative control (Inh-NC), siRNAs duplexes targeting human
MEKK2 (siMEKK2-1 or siMEKK2-2) and cyclin D1 (sicyclin
D1-1 or sicyclin D1-2) [25,26] were synthesized and purified by
RiboBio (Guangzhou, China). SiRNA duplexes with non-specific
sequences were used as siRNA negative control (NC). RNA
oligonucleotides were transfected by using Lipofectamine RNAi-
MAX (Invitrogen) and medium was replaced 6 hours after
transfection. A final concentration of 100 nM miR-520b,
200 nM Inh-520b, 100 nM siMEKK2 or 100 nM sicyclin D1
was used unless indicated. RNA transfection efficiency is
approximately 70%–80% and the overexpression of miRNA or
siRNA persists for at least 48 hours. Lipofectamine 2000
(Invitrogen) was used for transfection of plasmid alone or together
with RNA oligonucleotides. All oligonucleotide sequences are
listed in Table S2.
Colony formation assay
HepG2, H7402 and MHCC-97L cells were seeded in 6-well
plates. Cells were transfected with plasmids of pcDNA3, pcDNA3-
520b or siRNAs targeting MEKK2 or cyclin D1. Forty-eight hours
after transfection of pcDNA3-520b, the medium was replaced with
fresh medium containing G418 to kill untransfected cells. Cells
were grown for 9 to 14 days with fresh media. G418 was added
every 3 days in pcDNA3- or pcDNA3-520b-transfected cells.
Once colonies were visible, they were stained with methylene blue
and photographed. All experiments were performed at least three
times. The expression levels of miR-520b, MEKK2 or cyclin D1
in transfected cells were confirmed by qRT-PCR or western blot
anlysis.
Analysis of cell proliferation
Cell proliferation was determined by MTT (Sigma, Aaint Louis,
MI) assay as described previously [27] and EdU incorporation
assay was carried out using the Cell-Light TM EdU imaging
detecting kit according to the manufacturer’s instructions
(RiboBio). EdU is a thymidine analog whose incorporation can
be used to label cells undergoing DNA replication [28].
Flow cytometry analysis
After 48 hours transfection as earlier described, the cells (1610
6)
were harvested and washed twice with PBS. Washed cells were
resuspended in 0.6 mL PBS, and fixed by the addition of 1.4 mL
100% ethanol at 4uC overnight. The fixed cells were rinsed twice
with PBS, and resuspended in propidium iodine (PI) solution,
including 50 mg/mL PI and 50 mg/mL RNaseA (Sigma) in PBS
without calcium and magnesium, and incubated at 37uC for
30 minutes in the dark. Stained cells were passed through a nylon-
mesh sieve to remove cell clumps and analyzed by a FACScan
flow cytometer and Cell Quest analysis software (Becton
Dickinson, San Jose, CA, USA). Flow cytometry analysis was
repeated 3 times.
Dual-Luciferase reporter gene assay
Luciferase reporter gene assay was performed using the Dual-
Luciferase Reporter Assay System (Promega) according to the
manufacturer’s instructions. Cells of 90% confluence were seeded
in 24-well plates. For MEKK2 39UTR and cyclin D1 39UTR
luciferase reporter assay, wild type or mutant reporter constructs
(termed WT or Mut) were co-transfected into HepG2 cells in 24-
well plates with 100 nM miR-520b or 100 nM miR-NC and
Renilla plasmid by using lipofectamine 2000 (Invitrogen).
Reporter gene assays were performed 48 hours post-transfection
using the Dual luciferase assay system (Promega, Madison, WI).
Firefly luciferase activity was normalized for transfection efficiency
using the corresponding Renilla luciferase activity. All experiments
were performed at least three times.
Western blot analysis
Cells were washed in phosphate-buffered saline (PBS), and
cellular proteins were extracted in RIPA buffer (Biomed, China).
Lysates were cleared by centrifugation, and proteins were
separated by gel electrophoresis. Membranes were blocked in
PBS-0.1% Tween20 (PBS-T)/5% (w/v) milk for 1 hour at room
temperature. Membranes were then incubated with primary
antibodies diluted in PBS-T for 2 hours at room temperature.
Subsequently, membranes were washed with PBS-T and incubat-
ed with peroxidase-conjugated secondary antibody diluted in PBS-
T at room temperature for 1 hour. Membranes were washed in
PBS-T and bound antibody was detected by enhanced chemilu-
minescence system Western Blotting Detection Reagents (Amer-
sham Biosciences, Buckinghamshire, UK). Forty-eight hours after
transfection, Western blot analysis was performed as above. The
primary antibodies were mouse anti-human cyclin D1 monoclonal
antibody (Santa Cruz, USA), rabbit anti-human MEKK2
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monoclonal antibody (Santa Cruz), mouse anti-human p-JNK
monoclonal antibody (Santa Cruz) and mouse anti-human b-actin
(Sigma). All experiments were repeated at least three times.
Tumorigenicity in nude mice
All experimental procedures involving animals were in accor-
dance with the Guide for the Care and Use of Laboratory Animals (NIH
publications Nos. 80-23, revised 1996) and were performed
according to the institutional ethical guidelines for animal
experiment. BALB/c nude mice were employed for tumorigenicity
analysis. The tumorigenicity of the stably pcDNA3-520b- or
pcDNA3-transfected HepG2 cells was measured as follows. Forty-
eight hours after transfection of pcDNA3-520b, the medium was
replaced with fresh medium containing G418 to kill untransfected
cells. HepG2 cells were transfected with NC or siRNAs targeting
MEKK2 or cyclin D1. Forty-eight hours after transfection, cells
were harvested by trypsinization, washed twice with sterile PBS,
and resuspended at a concentration of 1610
7 cells/ml. Aliquots of
0.1–0.2 ml were injected subcutaneously into six 4- to 6-week-old
Balb/c athymic nude mice. Tumor growth was measured after 3
days from injection and then every 3 days. Tumor volume (V) was
monitored by measuring the length (L) and width (W) with calipers
and calculated with the formula (L6W
2)60.5. Photographs were
taken 4 weeks after the injection.
Statistical analysis
All values are presented as means 6 S.E.M. Each experiment
was repeated at least 3 times. Statistical analysis was performed by
the Student’s t test. P,0.05 was considered significant. All
statistical analysis was performed using SPSS13.0 software
(Chicago, IL).
Supporting Information
Figure S1 MiR-520b inhibits expression of MEKK2 and
cyclin D1 in tumors from mice in figure 3. The
expression levels of MEKK2 and cyclin D1 in excised
tumor tissues from mice were examined by western blot
analysis.
(TIF)
Figure S2 MiR-520b decreases the levels of p-JNK and
siMEKK2 abolishes levels of p-JNK in hepatoma cells.
The effect of miR-520b, siMEKK2-1 on phosphorylation levels of
JNK (p-JNK) in HepG2 and H7402 cells was examined by
western blot analysis. b-actin was used as an internal control.
(TIF)
Table S1 The characteristics of clinical HCC patients.
(DOC)
Table S2 Sequences of DNA and RNA oligonucleotides.
(DOC)
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